RPG Life Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
October 18, 2023 at 01:54 pm
Share
RPG Life Sciences Limited reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported sales was INR 1,535.8 million compared to INR 1,347.9 million a year ago. Revenue was INR 1,554.1 million compared to INR 1,360.2 million a year ago. Net income was INR 258.6 million compared to INR 199.7 million a year ago. Basic earnings per share from continuing operations was INR 15.64 compared to INR 12.08 a year ago. Diluted earnings per share from continuing operations was INR 15.64 compared to INR 12.08 a year ago.
For the six months, sales was INR 3,013.6 million compared to INR 2,637.2 million a year ago. Revenue was INR 3,050 million compared to INR 2,661.7 million a year ago. Net income was INR 479.6 million compared to INR 381.8 million a year ago. Basic earnings per share from continuing operations was INR 29 compared to INR 23.09 a year ago. Diluted earnings per share from continuing operations was INR 29 compared to INR 23.09 a year ago.
RPG Life Sciences Limited is an India-based pharmaceutical company. The Company operates in the domestic and international markets in the formulations, generics, and synthetic active pharmaceutical ingredients (APIs) space. Its business portfolio includes domestic formulations, international formulations and APIs. Its domestic formulation business manufactures and markets branded finished dosage formulations in India. The domestic formulations business has presence in over 10 therapeutic areas, including nephrology, oncology, rheumatology, cardiology, respiratory, nutritional, gastroenterology, and diabetology, among others. The international formulations business is involved in developing, manufacturing and marketing oral solid formulations in the generic and branded generic space across regulated and emerging markets. Its products include Azoran, Mofetyl, Arpimune ME, Azathioprine, Sodium Valproate PR, Nicorandil, Quinfamide, Nicorandil, Haloperidol, Risperidone, and others.